trending Market Intelligence /marketintelligence/en/news-insights/trending/p229ajokef8eowuae6ekcg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Motif Bio submits application for antibiotic medicine with US FDA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Motif Bio submits application for antibiotic medicine with US FDA

Motif Bio PLC submitted an application with the U.S. Food & Drug Administration, seeking approval to market its investigational antibiotic for treating bacterial skin infections.

The New York-based biopharmaceutical company said it submitted a new drug application with the U.S. regulator for iclaprim, which was evaluated in two successful phase 3 trials.

Iclaprim is expected to receive priority review, meaning the U.S. FDA will make a decision on the medicine within six months instead of the standard 10-month review period.

The drug may also be eligible for 10 years of market exclusivity in the U.S.